

REMARKS

The examiner's restriction requirement is based on original claims 1-18 which applicants intended to replace in their preliminary amendment with new claims 1-17. The present amendment cancels original claims 1-18 and replaces these with new claims 19-35, substantially the same as previously submitted claims 1-17.

Applicants respectfully elect Group I as defined by the examiner, with traverse, and request that present claims 19-35 be considered together in the present application. New claims 19-28 are directed to a process for identifying and selecting compounds for the treatment of cerebrovascular disorders, and new claims 29-35 are drawn to methods of treating these disorders with the identified and selected compounds. The processes share a special technical feature in that each involves the isolation or use of compounds which selectively bind to 5-HT₅ receptors.

In view of the foregoing amendments and remarks, applicants consider that the rejections of record have been obviated and respectfully solicit passage of the application to issue.

A check in the amount of \$110.00 is attached to cover the required one month extension fee.

Please charge any shortage in fees due in connection with the filing of this paper, including Extension of Time fees to Deposit Account No. 11-0345. Please credit any excess fees to such deposit account.

Respectfully submitted,
KEIL & WEINKAUF



David C. Liechty
Reg. No. 48,692

1350 Connecticut Ave., N.W.
Washington, D.C. 20036
(202)659-0100

DCL/kas